Thornburg Investment Management Inc. Trims Position in Insulet Corporation $PODD

Thornburg Investment Management Inc. trimmed its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 8.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,049 shares of the medical instruments supplier’s stock after selling 1,421 shares during the period. Thornburg Investment Management Inc.’s holdings in Insulet were worth $4,728,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Zions Bancorporation National Association UT purchased a new position in shares of Insulet during the first quarter worth $26,000. SouthState Corp boosted its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new position in Insulet in the second quarter valued at approximately $32,000. Golden State Wealth Management LLC increased its holdings in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares in the last quarter. Finally, Trust Co. of Toledo NA OH acquired a new position in shares of Insulet in the 2nd quarter valued at $35,000.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Stifel Nicolaus started coverage on Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target for the company. Leerink Partners lifted their price target on shares of Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Jefferies Financial Group upped their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, Canaccord Genuity Group set a $432.00 target price on Insulet in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $379.65.

Insider Buying and Selling at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.39% of the company’s stock.

Insulet Stock Performance

NASDAQ PODD opened at $326.80 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock’s fifty day moving average is $322.19 and its two-hundred day moving average is $316.21. The firm has a market capitalization of $22.99 billion, a P/E ratio of 99.33, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter in the previous year, the company posted $1.08 EPS. The company’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.